EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Validated antimalarial drug target discovery using genome-scale metabolic modeling

Supannee Taweechai, Francis Isidore Garcia Totañes, David Westhead, Clara Herrera-Arozamena, Richard Foster, Glenn A McConkey iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00459-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Supannee Taweechai und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biology, Molecular & Cell Biology, University of Leeds, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Drug Discovery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the rapid resistance of Plasmodium falciparum to antimalarial drugs, there is a continual need for new treatments. A genome-scale metabolic (GSM) model was developed with integrated metabolomics and constraint-based, experimental flux-balance data to predict genes essential for P. falciparum growth as drug targets. We selected the highly ranked P. falciparum UMP-CMP kinase (UCK) to test its necessity and the ability to inhibit parasite growth in the presence of inhibitors. Conditional deletion mutants using the DiCre recombinase system, generated by CRISPR-Cas genome editing, exhibited defective asexual growth and stage-specific developmental arrest. Based on in silico and in vitro screening, inhibitors were identified that are selective for P. falciparum UCK and exhibit antiparasitic activity. This study, for the first time, shows assertions from a GSM model identifying novel, validated “druggable” targets. These findings show a role for GSM models in antimalarial drug discovery and identify P. falciparum UCK as a novel, valid malaria drug target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium falciparumDrug DiscoveryGenome, ProtozoanHumansMalaria, FalciparumCRISPR-Cas SystemsProtozoan Proteins

Stichwörter der Autor:innen

CRISPR-Casdruggablefalciparumflux-balance analysisgenome-scale metabolic modelmalariapyrimidinetarget

Substanzen

AntimalarialsProtozoan Proteins

Autor:innen und Institutionen

  • School of Biology, Molecular & Cell Biology, University of Leeds, Leeds, United Kingdom.
  • School of Chemistry, University of Leeds, Leeds, United Kingdom.

ORCID-Profile: Glenn A McConkey

Zitieren

APA

Taweechai, S., Totañes, F. I. G., Westhead, D., Herrera-Arozamena, C., Foster, R., & McConkey, G. A. (2025). Validated antimalarial drug target discovery using genome-scale metabolic modeling. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00459-25

Vancouver

Taweechai S, Totañes FIG, Westhead D, Herrera-Arozamena C, Foster R, McConkey GA. Validated antimalarial drug target discovery using genome-scale metabolic modeling. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00459-25

BibTeX
@article{Taweechai2025,
  author = {Taweechai, Supannee and Totañes, Francis Isidore Garcia and Westhead, David and Herrera-Arozamena, Clara and Foster, Richard and McConkey, Glenn A},
  title = {Validated antimalarial drug target discovery using genome-scale metabolic modeling},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00459-25}
}
Kostenlos starten →